| BITRF Stock | | | USD 0.03 0.03 973.33% |
Use the math transform workspace to apply Inverse Tangent Over Price Movement transformation and other studies to Biotron. The focus on price transformations that reveal shifts in trend structure helps organize trend, volatility, and risk context for Biotron.
Most technical analysis of Biotron help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Biotron from various momentum indicators to cycle indicators. When you analyze Biotron charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia. Biotron operates under Biotechnology classification in the United States and is traded on OTC Exchange. As a micro-cap equity, Biotron is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/B of 23.61, profit margin of -1.78%. Biotron has a market cap of 18.67 M, ROE of -112.24%.
Methodology
Unless otherwise specified, financial data for Biotron Limited is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Biotron (USA Stocks:BITRF) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Underlying inputs rely on public filings and market reference sources, including disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR. Values may reflect publication timing differences. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Biotron Limited may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial Board
Tracking Biotron inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.